ATE525400T1 - Verwendung trifunktionaler antikörper zur risikoreduzierung von gvhd in einer allogenetischen anti-tumor zelltherapie - Google Patents

Verwendung trifunktionaler antikörper zur risikoreduzierung von gvhd in einer allogenetischen anti-tumor zelltherapie

Info

Publication number
ATE525400T1
ATE525400T1 AT04028473T AT04028473T ATE525400T1 AT E525400 T1 ATE525400 T1 AT E525400T1 AT 04028473 T AT04028473 T AT 04028473T AT 04028473 T AT04028473 T AT 04028473T AT E525400 T1 ATE525400 T1 AT E525400T1
Authority
AT
Austria
Prior art keywords
antibodies
tumor cell
binding
allogenetic
gvhd
Prior art date
Application number
AT04028473T
Other languages
English (en)
Inventor
Horst Lindhofer
Shoshana Morecki
Shimon Slavin
Original Assignee
Trion Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trion Pharma Gmbh filed Critical Trion Pharma Gmbh
Application granted granted Critical
Publication of ATE525400T1 publication Critical patent/ATE525400T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04028473T 2004-12-01 2004-12-01 Verwendung trifunktionaler antikörper zur risikoreduzierung von gvhd in einer allogenetischen anti-tumor zelltherapie ATE525400T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04028473A EP1666500B1 (de) 2004-12-01 2004-12-01 Verwendung trifunktionaler Antikörper zur Risikoreduzierung von GvHD in einer allogenetischen anti-Tumor Zelltherapie

Publications (1)

Publication Number Publication Date
ATE525400T1 true ATE525400T1 (de) 2011-10-15

Family

ID=34927607

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04028473T ATE525400T1 (de) 2004-12-01 2004-12-01 Verwendung trifunktionaler antikörper zur risikoreduzierung von gvhd in einer allogenetischen anti-tumor zelltherapie

Country Status (2)

Country Link
EP (1) EP1666500B1 (de)
AT (1) ATE525400T1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
ES2460517T3 (es) 2005-07-25 2014-05-13 Emergent Product Development Seattle, Llc Reducción de células b mediante el uso de moléculas de unión específica a cd37 y de unión específica a cd20
EP2418223A3 (de) 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Einkettige, multivalente Bindungsproteine mit Effektorfunktion
PT2132228E (pt) 2008-04-11 2011-10-11 Emergent Product Dev Seattle Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
EP2524699A1 (de) * 2011-05-17 2012-11-21 Trion Research GmbH Impfstoffzubereitung mit trifunktionalen Antikörpern mit Antigenimmunogenität verbessernden Eigenschaften
US9750806B2 (en) 2011-05-17 2017-09-05 Trion Research Gmbh Vaccine preparation containing trifunctional antibodies with antigen immunogenicity enhancer properties
CN106366189A (zh) * 2015-07-22 2017-02-01 中国医学科学院肿瘤医院 一种抗人肺癌干细胞的单克隆抗体
MX2018003292A (es) 2015-09-21 2018-08-01 Aptevo Res & Development Llc Polipéptidos de unión a cd3.
TWI905099B (zh) 2019-05-21 2025-11-21 瑞士商諾華公司 Cd19 結合分子及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19725586C2 (de) * 1997-06-17 1999-06-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von Zellpräparaten zur Immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer Antikörper
AU2002323236A1 (en) * 2001-08-17 2003-03-03 Gerlad Elfenbein In situ immunization

Also Published As

Publication number Publication date
EP1666500A1 (de) 2006-06-07
EP1666500B1 (de) 2011-09-21

Similar Documents

Publication Publication Date Title
ATE294591T1 (de) Verwendung von trifunktionellen bispezifischen und trispezifischen antikörpern zur behandlung von malignem aszites
EA202192090A1 (ru) Антигенсвязывающие белки против гамма-цепи рецептора il2
DK1771474T3 (da) Inhibitorer af angiopoitin-like 4 protein, kombinationer og anvendelser deraf
IL311603B1 (en) Bispecific antibodies and compounds containing them for cancer treatment
CY1110874T1 (el) Μεθοδοι θεραπειας για συμπαγεις ογκους που εκφραζουν to cd40 αντιγονο κυτταρικης επιφανειας
DK1565489T3 (da) Internaliserende antistoffer specifikke for RAAG10-celleoverflademålet
MXPA05012723A (es) Tratamiento con anticuerpos anti-vgf.
IS8432A (is) Mótefni sem bindast viðtaka hvítfrumuboða-4
CR9477A (es) Numero de copias del gen del receptor del factor de crecimiento epidermico
ATE526987T1 (de) Dr5-antikörper und deren verwendung
WO2010059969A3 (en) Use of anti-vegf antibody in combination with chemtherapy for treating breast cancer
RU2599417C3 (ru) Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
EA200801172A1 (ru) Лиганды, имеющие специфичность связывания в отношении рецептора эпидермального фактора роста (egfr) и/или сосудистого эндотелиального фактора роста (vegf), и способы их применения
ATE538136T1 (de) Antikörper gegen connective tissue growth factor
ZA200709780B (en) Anti-EGFR antibody therapy based on an increased copy number of the EGFR gene in tumor tissues
ATE469658T1 (de) Kombinationstherapien gegen multiple toll-like- rezeptoren und ihre verwendung
ATE525400T1 (de) Verwendung trifunktionaler antikörper zur risikoreduzierung von gvhd in einer allogenetischen anti-tumor zelltherapie
EP2275445A3 (de) Ephb4-bindende Antikörper zur Inhibierung von Angiogenese und Tumorwachstum
WO2024173607A3 (en) Combination of bispecific antibodies and chimeric antigen receptor t cells for treatment
GB0102145D0 (en) Substances
UA104741C2 (uk) Моноклональні антитіла проти феропортину 1 та варіанти їх застосування
WO2006027693A3 (en) Tumor specific genes and variant RNAS and uses thereof as targets for cancer therapy and diagnosis
EA200900735A1 (ru) Применение слитого антигена mage a3-белок d в имунотерапии в сочетании с хирургическим вмешательством, химиотерапией или радиотерапией для лечения рака
DE60231971D1 (de) Ndet, und seine verwendung zur behandlung von krebs
MX2021008453A (es) Formulaciones de anticuerpos que se unen a cd137 humano y usos de los mismos.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties